United States securities and exchange commission logo





                          November 18, 2020

       Jeremy M. Levin, DPhil, MB Chir
       Chief Executive Officer
       Ovid Therapeutics Inc.
       1460 Broadway
       Suite 15044
       New York, NY 10036

                                                        Re: Ovid Therapeutics
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed November 13,
2020
                                                            File No. 333-250054

       Dear Dr. Levin:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Ada D.
Sarmento at 202-551-3798 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Jaime L. Chase, Esq.